Beta-asarone is a phenylpropanoid most strongly associated with Acorus calamus and related Acorus materials, where it can dominate beta-asarone chemotypes. The public evidence base is unusually safety-heavy for an aroma constituent: identity and occurrence are clear, several preclinical studies describe antifungal or cell-model effects, but toxicology reviews and European food-safety opinions repeatedly flag mutagenicity and carcinogenicity concerns. Consumer-facing copy should therefore treat beta-asarone mainly as a restricted constituent with research interest, not as a wellness-active ingredient.
Chemical identity and composition
PubChem identifies beta-asarone as C12H16O3 with the Z-propenyl trimethoxybenzene structure. In the archive's calamus-root oil record, beta-asarone is the dominant constituent in a beta-asarone chemotype batch at 80.21%, with trans-beta-asarone as a secondary related marker at 9.91%.
Aroma and practical use
- Use the recorded spicy, warm, sweet, herbal, herbaceous, woody, calamus-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A toxicology review concluded that beta-asarone has published evidence for cardiotoxicity, hepatotoxicity, reproductive toxicity, mutagenicity, and carcinogenicity, with official restrictions based on exposure concerns.
The review assessed available asarone-isomer toxicology and found beta-asarone to be the isomer most directly addressed by restrictions and recommendations.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
An isolated-compound antifungal study reported complete inhibition of some plant pathogenic fungi and reduced lesion formation in infected rice and cucumber leaves.
The abstract reports complete inhibition of several fungal species in vitro and substantial suppression of disease lesions in plant models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A LoVo colon-cancer study reported dose- and time-dependent loss of viability with apoptosis signals in vitro and reduced xenograft tumor volume in mice.
The paper linked the effect to mitochondrial and caspase pathways, but this remains oncology-model evidence and not a basis for consumer health claims.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · IFRA Standard 110 (Amendment 40): cis- and trans-Asarone is a Prohibited fragrance substance (CAS 5273-86-9 among the covered isomers) - not permitted as a fragrance ingredientScreening assumption (verified). It is not a verified constituent-specific exposure limit.
model fallback · IFRA Standard 110 (Amendment 40): cis- and trans-Asarone is a Prohibited fragrance substance (CAS 5273-86-9 among the covered isomers) - not permitted as a fragrance ingredientA European Scientific Committee on Food opinion described beta-asarone as having weak carcinogenic effects in rats at 20 mg/kg bw/day and above and treated mutagenicity concern as unresolved enough to require strict exposure control.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The archive's calamus-root oil file already applies a 0.01% total asarone finished-product ceiling based on public IFRA-style restriction material for cis- and trans-asarone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the public evidence base is dominated by toxicology and preclinical assays, beta-asarone should not be framed as a routine wellness constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
mitochondrial_caspase_apoptosis_signaling
A colon-cancer xenograft and cell study reported beta-asarone-associated apoptosis with decreased mitochondrial membrane potential, a lower Bcl-2:Bax ratio, and activation of caspase-9 and caspase-3.
This experimental finding does not establish benefit, dose or safety in people using this blend.
fungal_growth_inhibition
An antifungal paper reported complete inhibition of mycelial growth in several plant fungal pathogens across tested concentrations, supporting a direct growth-inhibitory preclinical mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (4)
- This pass did not verify a constituent-specific modern human clinical trial establishing safe oral, topical, or inhalation use of isolated beta-asarone.
- Public benefit-oriented studies exist, but the safety signal is strong enough that future upgrades should continue to foreground restriction and hazard data.
- The archive currently separates beta-asarone from trans-beta-asarone; future curation may want a clearer house rule for handling asarone stereoisomer naming across oil files.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.